Is High‐Intensity Statin Therapy Associated With Lower Statin Adherence Compared With Low‐ to Moderate‐Intensity Statin Therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: The recent cholesterol guideline recommends high‐intensity statins in cardiovascular disease (CVD) patients. High‐intensity statins are associated with more frequent side effects. Therefore, it may be of concern that these recommendations might reduce statin adherence. Hypothesis: High‐intensity statins are associated with lower adherence compared with low‐ to moderate‐intensity statins. Methods: In a national database of 972 532 CVD patients from the Veterans Health Administration, we identified patients receiving statins between October 1, 2010, and September 30, 2011. We assessed statin adherence by calculating proportion of days covered (PDC) and determined whether high‐intensity statin therapy was independently associated with a lower PDC. Results: Statins were prescribed in 629 005 (64.7%). Of those, 229 437 (36.5%) received high‐intensity statins. Mean PDC (0.87 vs 0.86, P < 0.0001) and patients with PDC ≥0.80 (76.3% vs 74.2%, P < 0.0001) were slightly higher for those receiving low‐ to moderate‐intensity compared with high‐intensity statins. In adjusted analyses, high‐intensity statin use was associated with a significant but modest PDC reduction compared with low‐ to moderate‐intensity statin use, whether PDC was assessed as a continuous (β‐coefficient: −0.008, P < 0.0001) or categorical (PDC ≥0.80 [odds ratio: 0.94, 95% confidence interval: 0.93‐0.96]) measure of statin adherence. Conclusions: An approach of high‐intensity statin therapy will lead to a significant practice change, as the majority of CVD patients are not on high‐intensity therapy. However, this change may be associated with a very modest reduction in statin adherence compared with low‐ to moderate‐intensity therapy that is unlikely to be of clinical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.
Karve, S., Cleves, M. A., Helm, M., Hudson, T. J., West, D. S., & Martin, B. C. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903126833 · Cited by 620
Cited by
Rodriguez, F., Maron, D. J., Knowles, J. W., Virani, S. S., Lin, S., & Heidenreich, P. A. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4052 · Cited by 163
“Despite thegrowingevidence that statins consistently improveoutcomes for the secondarypreventionofASCVD, these medications continue tobeunderused in clinical practice.(23-27) Although the reasons for thisunderusearenot clear, onecause maybeanassumption thathigher-intensity statinsdonot confer an important benefit.”
BackgroundSelf-citationBempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
Bilen, O., & Ballantyne, C. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0611-4 · Cited by 119
Self-citationPokharel, Y., Tang, F., Jones, P. G., Nambi, V., Bittner, V. A., Hira, R. S., Nasir, K., Chan, P. S., Maddox, T. M., Oetgen, W. J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.5922 · Cited by 107
Self-citationAssociation Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System
Jia, X., Al Rifai, M., Ramsey, D. J., Ahmed, S. T., Akeroyd, J. M., Nambi, V., Ballantyne, C. M., Petersen, L. A., Stone, N. J., & Virani, S. S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.04.002 · Cited by 41
Self-citation
Metadata
- Authors
- Virani, S. S., Woodard, L. D., Akeroyd, J. M., Ramsey, D. J., Ballantyne, C. M., & Petersen, L. A.
- Venue
- Clinical Cardiology
- Publisher
- Wiley
- Published
- 2014-10-16
- Volume
- 37
- Issue
- 11
- Pages
- 653-659
- ISSN
- 0160-9289 (ISSN-L)
- 1932-8737
- OpenAlex
- W1506880006
- Cited by
- 62
- References
- 4
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.